Debunking 7 Common Misconceptions About The COVID-19 Vaccine binnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from binnews.com Daily Mail and Mail on Sunday newspapers.
U.S. Life Expectancy Drops 1 Full Year Due to COVID-19
By Dennis Thompson
HealthDay Reporter
THURSDAY, Feb. 18, 2021 (HealthDay News) In a sign that the coronaviruspandemic is cutting short the lives of Americans, a new government report finds that average life expectancy in the United States took a drastic plunge during the first half of 2020, particularly among Black and Hispanic people.
Overall U.S. life expectancy dropped to 77.8 years, down one full year from the 78.8 years estimated in 2019.
Declines were even greater for certain demographics. For example, average life expectancy decreased 2.7 years for Black people and 1.9 for Hispanic people between 2019 and the first half of 2020, according to the National Center for Health Statistics (NCHS), which is part of the U.S. Centers for Disease Control and Prevention. Life expectancy for white people decreased by an average 0.8 years.
A pair of small studies found that patients previously infected with COVID-19 given their first vaccine dose showed the sort of robust immune response that people generally tend to have following their second dose.
E-Mail
Thursday, January 28, 2021, CLEVELAND: The National Institutes of Health has awarded Cleveland Clinic a $6.7 million grant to evaluate if high-intensity exercise can prevent development of Alzheimer s disease. The five-year study will assess the effect of home-based indoor cycling in slowing disease progression in healthy older people at high genetic risk for developing the disease.
This represents the first randomized control trial to explore if a long-term exercise intervention program can alter progression of late-onset Alzheimer s disease in sedentary, high-risk individuals. If successful, the trial has the potential to provide a scalable, low-cost intervention capable of substantially reducing healthcare costs by modifying the trajectory of the disease.
Potential Target For Ulcerative Colitis Drugs by Pooja Shete on January 15, 2021 at 7:36 PM
The study conducted by researchers from Cleveland Clinic s Lerner Research Institute is published in the journal
Nature Communications.
The researchers used this model to identify a promising target that could be blocked to slow the disease progression. Ulcerative colitis occurs due to abnormal reactions of the immune system that lead to inflammation and ulcers on the inner lining of the large intestines. The condition is highly heterogeneous both in terms of patients symptoms and disease pathology.
Current therapy for ulcerative colitis mainly focuses on suppressing the overactive immune response with anti-inflammatory drugs. However, these therapies have limited long-term efficacy in ulcerative colitis patients.